Asymchem 2022 Annual Earnings Forecast
January 30- Asymchem released its annual earnings forecast for 2022. Annual revenue is expected to be approximately $1.5B and net profit attributed to shareholders of parent company is approximately $485M. During the reporting period, small molecule business grew and revenue is expected to grow over 115% year-on-year. With Asymchem’s technology-driven business strategy the company advances the development of chemical macromolecules, clinical CRO, formulation CDMO, biologics CDMO, and other emerging business segments. Its number of customers and projects continues to rise, accounting for a 145% growth year over year. Its China domestic market grew over 140% year-over-year.
Asymchem Facilitates the Clinical Approval of CTS2016 Capsule: A Targeted Oncology Drug of Cytosinlab Therapeutics co., ltd.
CytosinLab Therapeutics Co., Ltd. announced that CTS2016 capsule, a new generation of tumor targeting drug, was approved by the NMPA for clinical trials. During this project, Asymchem, its subsidiary Clin-nov, and its equity subsidiary Yugen Medtech, provided a variety of GXP services to ensure each key milestone was achieved quickly and efficiently. Clin-nov will perform services during phase 1 of the clinical trial in AML and MDS patients with moderate to high risk of myelodysplastic syndrome.
Asymbio Enters Into Strategic Partnership with Axcynsis for Development and Manufacturing of ADCs
AsymBio announced a long-term strategic collaboration with Axcynsis Therapeutics, a Singaporian startup company focused on the development of antibody-x couples (AXC). The collaboration will focus on the development and manufacturing of multiple antibody coupled drugs (ADCs) to accelerate the process of coupling drug innovation.
Asymchem Developed Gas-Liquid Mixing Reaction Device and Reaction System, Granted a Patent
The gas-liquid mixing reaction device and reaction system, developed by Asymchem, was granted a patent (CN218166971U). In this invention, the first gas-liquid distributor and the second gas-liquid distributor separate the shell into primary reaction and secondary reaction sections. By separating the reaction area inside the shell into multiple reaction sections, it effectively controls the re-mixing phenomenon of the reaction system and the aggregation phenomenon of bubbles. That maintains the multiphase reaction system close to the ideal advection flow state, which improves the controllability of the continuous gas-liquid multi-phase reaction.
Asymchem TJ Construction Projects
The construction projects of Asymchem TJ sites are progressing accordingly.
● The R&D center of CMMD in west plant (TJ4) is complete. The equipment verification of production building 1 is in progress and the D-level area will be put into use at the end of February.
● The API4 building on the north side of TJ3 is expected to be completed in February.
● Completion of the TJ construction projects will help Asymchem continue to increase production capacity, improve operational efficiency, and lay a solid foundation for the company’s strategic development.
Clin-Nov Medical’s 2022 Year-End Summary and 2023 Annual Management Meeting
January 14-15: Clin-nov Medical held the 2022 year-end summary and 2023 annual management meeting in Tianjin. The meeting summarized the work of 2022 and commended teams and individuals with outstanding achievements while making the overall planning and key initiatives for Clin-nov in 2023.
Dr. Jiwu Ruan officially joined Asymchem as Executive Directo of Center of Early Phase Process Synthesis (EPPS) on January 11, 2023. He will report directly to Vice General Manager, Dr. Jianhua Yu.
In this position, Dr. Ruan will be mainly be responsible for building out teams, establishing processes and the daily management of the business portfolio within the early project research and development center.
Dr. Ruan obtained his doctoral degree in Organic Chemistry from Zhongshan University in 2004. After graduation, he has been engaged in post-doctoral research at the Hong Kong Polytechnic University and the University of Liverpool (UK) for nearly 7 years. He mainly focused on asymmetric hydrogenation, asymmetric synthesis, and palladium catalyzed coupling reaction. He also has experience in Dr. Reddy’s Laboratory, an Indian generic drug company, Liverpool ChiroChem Pharmaceuticals, Nanjing PharmaBlock Sciences., Porton Pharma as R&D director.
Ms. Yanping Li joined Clin-nov Medical on January 3rd as Executive Director of Regulatory Affairs, reporting to Mr. Yin Qi, CSO & US Head of Clin-nov Medical.
In this role, Ms. Li will be responsible for the management of regulatory affairs in the Dept. of US Operation. This includes the management of development strategies and team members to further enhance Clin-nov’s capacity in managing US regulatory affairs.
Ms. Yanping Li graduated from Peking University Health Science Center with a doctoral degree in Chemical Biology. She has over 13 years of experience in drug registration and clinical science. She was in charge of multiple IND and NDA applications for innovative chemical drugs and biologics. Prior to Clin-Nov, Ms. Li worked at Simcere, Eddingpharm, and Bayer Healthcare as Senior Director of Regulatory Affairs and Director of Clinical Science, responsible for simultaneous development of innovative drugs in China and the US. As Director of Clinical Science in Simcere, she led a cross functional team to run a China-US clinical trial of anti-cancer drugs (FIC).
OPT Congress | March 13-14, 2023 | Boston, MA
Organic Process Research & Development | March 13-15 | Clearwater, FL
RNA Leaders Europe Congress | March 15-16, 2023 | Basel, Switzerland
DCAT Week | March 20-23 | New York, New York
Festival of Biologics | March 20-22, 2023 | San Diego Marina, CA
ACS Crossroads of Chemistry | March 26-30, 2023 | Indianapolis, IN
SCI Process Development Symposium | March 29-31, 2023 | Cambridge, UK
TIDES USA | May 7-10, 2023 | San Diego, CA
IOPC | June 5-7, 2023 | Milan, Italy
BIO Convention | June 5-8, 2023 | Boston, MA
BOS Basel | July 4-5, 2023 | Basel, Switzerland